Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Bioscience (RCUS) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer’s immunosuppressive mechanisms. This page provides investors and researchers with timely updates on the company’s developments in immuno-oncology, including advancements in its ATP-adenosine pathway research.
Access the latest press releases, clinical trial milestones, and financial disclosures in one centralized hub. Track updates on therapeutic candidates spanning small molecules and biologics, partnership announcements, and regulatory progress. Our curated news collection ensures you stay informed about RCUS’s efforts to address unmet needs in lung, colorectal, and pancreatic cancers.
Bookmark this page for real-time insights into Arcus Bioscience’s R&D pipeline, strategic initiatives, and industry positioning. Check back regularly for verified updates directly from corporate communications and trusted financial sources.
Arcus Biosciences (NYSE:RCUS) has announced the granting of equity awards to 13 new employees. The awards include options to purchase 28,900 shares at an exercise price of $33.70 per share and restricted stock units for a total of 14,450 shares. This action is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting key biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to eleven new employees, totaling options to purchase 30,950 shares at an exercise price of $32.98, the closing price on March 23, 2022. Additionally, restricted stock units were awarded for 15,475 shares. These grants were made under the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is focused on developing innovative cancer therapies, including six investigational medicines targeting various pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to 14 new employees. A total of 61,000 stock options at an exercise price of $33.03 per share and 30,500 restricted stock units were granted. These awards are part of the company's 2020 Inducement Plan approved by the Board of Directors in January 2020. Founded in 2015, Arcus focuses on developing innovative therapies for cancer treatment, with an emphasis on combination approaches targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced promising initial data for AB521, a HIF-2a inhibitor, suggesting it may outperform the only approved HIF-2a inhibitor. The findings were detailed at the ESMO Targeted Anticancer Therapies Congress on March 7-8, 2022. Future presentations will include PK/PD modeling for etrumadenant, quemliclustat, and zimberelimab at the ASCPT conference on March 16-18, 2022, and insights into enhancing anti-tumor immunity at AACR on April 8-13, 2022. The company is progressing with its clinical trials, particularly a Phase 1/1b study for AB521 in renal cancer.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to seven new employees, totaling 20,450 stock options at an exercise price of $30.01 per share, based on the February 23, 2022 closing price. Additionally, 10,225 restricted stock units were awarded. The grants fall under the 2020 Inducement Plan approved by the Board of Directors in January 2020, complying with NYSE regulations.
Arcus is committed to developing innovative cancer therapies and has advanced multiple investigational medicines into clinical studies.
Arcus Biosciences reported strong financial results for the fourth quarter and full year 2021, highlighting a net income of $279.4 million for Q4 compared to a net loss of $51.9 million in the previous year. Revenues surged to $354.5 million, significantly up from $9.5 million year-over-year, mainly due to Gilead's collaboration. The company holds approximately $1.4 billion in cash, ensuring funding into 2026. Arcus has multiple Phase 3 studies underway for its lead drug, domvanalimab, in various cancers, indicating robust pipeline growth.
Arcus Biosciences (NYSE: RCUS), a biopharmaceutical company focused on developing cancer therapies, announced participation in two upcoming investor conferences. The first is the SVB Leerink 11th Annual Global Healthcare Conference, scheduled for February 16, 2022, at 1:20 p.m. PT, and the second is the Barclay’s Global Healthcare Conference on March 17, 2022, at 1:35 p.m. ET. Live audio webcasts will be available on the Arcus Biosciences website, and replays will be accessible for two weeks after the events.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to six new employees, totaling 64,050 shares at an exercise price of $30.30, equivalent to the closing price on February 8, 2022. Additionally, 2,025 restricted stock units were awarded. These grants were made under the Company’s 2020 Inducement Plan, approved in January 2020, complying with NYSE regulations. Founded in 2015, Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted options to purchase 38,850 shares and restricted stock units for 925 shares to six new employees. The exercise price is set at $31.75, equivalent to the closing price on January 24, 2022. The equity awards comply with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus Biosciences is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to two new employees totaling 41,800 shares at an exercise price of $37.56, the closing price on January 10, 2022. This issuance is in accordance with the Company’s 2020 Inducement Plan, approved under NYSE rules. Founded in 2015, Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies targeting various cancer pathways.